Drugs / HPV 16/18 E6/E7- pulsed DC vaccines
HPV 16/18 E6/E7- pulsed DC vaccines
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03870113 | Apr 2019 → Mar 2022 | cervical intraepithelial neoplasia | Shenzhen People's Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-08-22 | Alnylam Pharmaceuticals | Results Alnylam and Collaborators Publish New Pre-clinical Results on Ex Vivo Applications of RNAi to Enhance Dendritic Cell Vaccines for Cancer alnylam.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-08-22 | Alnylam Pharmaceuticals | Alnylam and Collaborators Publish New Pre-clinical Results on Ex Vivo Applications of RNAi to Enhance Dendritic Cell Vaccines for Cancer alnylam.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV 16/18 E6/E7- pulsed DC vaccines | “To develop HPV 16/18 E6/E7- pulsed DC vaccines and evaluate the safety and efficacy of DC vaccines;” NCT03870113 ↗ |
| Known as | DC vaccine | “To develop HPV 16/18 E6/E7- pulsed DC vaccines and evaluate the safety and efficacy of DC vaccines;” NCT03870113 ↗ |
| Known as | DC vaccines | “To develop HPV 16/18 E6/E7- pulsed DC vaccines and evaluate the safety and efficacy of DC vaccines;” NCT03870113 ↗ |
| Known as | dendritic cell vaccines | “By this research, we aim to establish the HPV16/18 E6/E7 peptide library which could induce the strong anti-virus immune response and to vaccinate the CIN 1/2 patients with...” NCT03870113 ↗ |
| Modality | Vaccine | “To develop HPV 16/18 E6/E7- pulsed DC vaccines” NCT03870113 ↗ |
| Route | Other | “injected into the adjacent lymph-node” NCT03870113 ↗ |